Cited by 755Malaria Research and ControlBacterial Infections and VaccinesTravel-related health issues

The DOI matches its Crossref record; 30 of the 31 references it cites were found in a registry or an index.

A Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African Infants

Open access

The RTS,S Clinical Trials Partnership·2012·New England Journal of Medicine

DOI 10.1056/nejmoa1208394PMC PMC10915853

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: The candidate malaria vaccine RTS,S/AS01 reduced episodes of both clinical and severe malaria in children 5 to 17 months of age by approximately 50% in an ongoing phase 3 trial. We studied infants 6 to 12 weeks of age recruited for the same trial. METHODS: We administered RTS,S/AS01 or a comparator vaccine to 6537 infants who were 6 to 12 weeks of age at the time of the first vaccination in conjunction with Expanded Program on Immunization (EPI) vaccines in a three-dose monthly schedule. Vaccine efficacy against the first or only episode of clinical malaria during the 12 months after vaccination, a coprimary end point, was analyzed with the use of Cox regression. Vaccine efficacy against all malaria episodes, vaccine efficacy against severe malaria, safety, and immunogenicity were also assessed. RESULTS: The incidence of the first or only episode of clinical malaria in the intention-to-treat population during the 14 months after the first dose of vaccine was 0.31 per person-year in the RTS,S/AS01 group and 0.40 per person-year in the control group, for a vaccine efficacy of 30.1% (95% confidence interval [CI], 23.6 to 36.1). Vaccine efficacy in the per-protocol population was 31.3% (97.5% CI, 23.6 to 38.3). Vaccine efficacy against severe malaria was 26.0% (95% CI, -7.4 to 48.6) in the intention-to-treat population and 36.6% (95% CI, 4.6 to 57.7) in the per-protocol population. Serious adverse events occurred with a similar frequency in the two study groups. One month after administration of the third dose of RTS,S/AS01, 99.7% of children were positive for anti-circumsporozoite antibodies, with a geometric mean titer of 209 EU per milliliter (95% CI, 197 to 222). CONCLUSIONS: The RTS,S/AS01 vaccine coadministered with EPI vaccines provided modest protection against both clinical and severe malaria in young infants. (Funded by GlaxoSmithKline Biologicals and the PATH Malaria Vaccine Initiative; RTS,S ClinicalTrials.gov number, NCT00866619.).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmoa1208394

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Modeling Survival Data: Extending the Cox Model
Therneau, T. M., & Grambsch, P. M. (2000) · Statistics for Biology and Health · doi:10.1007/978-1-4757-3294-8 · Cited by 8,674
Development of Virus-Like Particle Technology from Small Highly Symmetric to Large Complex Virus-Like Particle Structures
Pushko, P., Pumpens, P., & Grens, E. (2013) · Intervirology · doi:10.1159/000346773 · Cited by 5,975
First Results of Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African Children
The RTS, S. C. T. P. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1102287 · Cited by 896
Self-citation
ICH Harmonised Tripartite Guideline: Guideline for Good Clinical Practice.
Bhuiyan, P. S., & Rege, N. N. (2001) · PubMed · Cited by 527
Randomized, Double‐Blind, Phase 2a Trial of Falciparum Malaria Vaccines RTS,S/AS01B and RTS,S/AS02A in Malaria‐Naive Adults: Safety, Efficacy, and Immunologic Associates of Protection
Kester, K. E., Cummings, J. F., Ofori‐Anyinam, O., Ockenhouse, C. F., Krzych, U., Moris, P., Schwenk, R., Nielsen, R. A., Debebe, Z., Pinelis, E., et al. (2009) · The Journal of Infectious Diseases · doi:10.1086/600120 · Cited by 524
Mechanisms by which maternal antibodies influence infant vaccine responses: review of hypotheses and definition of main determinants
Siegrist, C. (2003) · Vaccine · doi:10.1016/s0264-410x(03)00342-6 · Cited by 350
Design and Analysis of Vaccine Studies
Halloran, M. E., Longini, I. M., & Struchiner, C. J. (2009) · Statistics for biology and health · doi:10.1007/978-0-387-68636-3 · Cited by 332
Safety of the RTS,S/AS02D candidate malaria vaccine in infants living in a highly endemic area of Mozambique: a double blind randomised controlled phase I/IIb trial
Aponte, J. J., Aide, P., Renom, M., Mandomando, I., Bassat, Q., Sacarlal, J., Manaca, M. N., Lafuente, S., Barbosa, A., Leach, A., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61542-6 · Cited by 279
Glycoconjugate vaccines and immune interference: A review
Dagan, R., POOLMAN, J. T., & Siegrist, C. (2010) · Vaccine · doi:10.1016/j.vaccine.2010.06.026 · Cited by 270
Safety and Immunogenicity of RTS,S/AS02D Malaria Vaccine in Infants
Abdulla, S., Oberholzer, R., Juma, O. A., Kubhoja, S. D., Machera, F., Membi, C. D., Omari, S., Urassa, A., Mshinda, H., Jumanne, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0807773 · Cited by 239

Flagged first, then by citations

Show all 31 references

1 of the 31 references couldn’t be matched to a known paper.

Research works printed but not linked: 1

Brabin B, 1990, Trop Dis Bull, 87, R1

Sorted by citations

Items 101–200 of 755

Costs of vaccine programs across 94 low- and middle-income countries
Portnoy, A., Ozawa, S., Grewal, S. K., Norman, B. A., Rajgopal, J., Gorham, K. M., Haidari, L. A., Brown, S. T., & Lee, B. Y. (2015) · Vaccine · doi:10.1016/j.vaccine.2014.12.037 · Cited by 90
Baseline exposure, antibody subclass, and hepatitis B response differentially affect malaria protective immunity following RTS,S/AS01E vaccination in African children
Ubillos, I., Ayestaran, A., Nhabomba, A. J., Dosoo, D., Vidal, M., Jiménez, A., Jairoce, C., Sanz, H., Aguilar, R., Williams, N. A., et al. (2018) · BMC Medicine · doi:10.1186/s12916-018-1186-4 · Cited by 87
A Next-generation Genetically Attenuated Plasmodium falciparum Parasite Created by Triple Gene Deletion
Mikolajczak, S. A., Lakshmanan, V., Fishbaugher, M. E., Camargo, N. M., Harupa, A., Kaushansky, A., Douglass, A. N., Baldwin, M., Healer, J., O’Neill, M. T., et al. (2014) · Molecular Therapy · doi:10.1038/mt.2014.85 · Cited by 90
Malaria in infants aged less than six months - is it an area of unmet medical need?
D’Alessandro, U., Ubben, D., Hamed, K. A., Ceesay, S. J., Okebe, J., Taal, M. A., Lama, E. K., Keïta, M., Koivogui, L., Nahum, A., et al. (2012) · Malaria Journal · doi:10.1186/1475-2875-11-400 · Cited by 91
Sporozoite immunization of human volunteers under chemoprophylaxis induces functional antibodies against pre-erythrocytic stages of Plasmodium falciparum
Behet, M. C., Foquet, L., van Gemert, G., Bijker, E. M., Meuleman, P., Leroux-Roels, G. G., Hermsen, C. C., Scholzen, A., & Sauerwein, R. W. (2014) · Malaria Journal · doi:10.1186/1475-2875-13-136 · Cited by 86
Vaccines Against Malaria
Ouattara, A., & Laurens, M. B. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/ciu954 · Cited by 85
Development of a transmission-blocking malaria vaccine: Progress, challenges, and the path forward
Nunes, J. K., Woods, C., Carter, T., Raphael, T., Morin, M. J., Diallo, D. A., Leboulleux, D., Jain, S. K., Loucq, C., Kaslow, D. C., et al. (2014) · Vaccine · doi:10.1016/j.vaccine.2014.07.030 · Cited by 85
RTS,S: Toward a first landmark on the Malaria Vaccine Technology Roadmap
Kaslow, D. C., & Biernaux, S. (2015) · Vaccine · doi:10.1016/j.vaccine.2015.09.061 · Cited by 92
Pre-erythrocytic antibody profiles induced by controlled human malaria infections in healthy volunteers under chloroquine prophylaxis
Felgner, P. L., Roestenberg, M., Liang, L., Hung, C., Jain, A., Pablo, J. V., Nakajima‐Sasaki, R., Molina, D. M., Teelen, K., Hermsen, C. C., et al. (2013) · Scientific Reports · doi:10.1038/srep03549 · Cited by 84
Controlled Human Malaria Infection
Spring, M., Polhemus, M., & Ockenhouse, C. F. (2014) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiu063 · Cited by 84
Proteolytic Cleavage of thePlasmodium falciparumCircumsporozoite Protein Is a Target of Protective Antibodies
Espinosa, D. A., Gutierrez, G. M., Rojas-López, M., Noe, A. R., Shi, L., Tse, S., Sinnis, P., & Zavala, F. P. (2015) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiv154 · Cited by 86
Vaccine development: Current trends and technologies
Poria, R., Kala, D., Nagraik, R., Walia, Y., Dhir, S., Singh, B., Kaushik, N. K., Noorani, M. S., Kaushal, A., & Gupta, S. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.122331 · Cited by 90
Variant surface antigens of malaria parasites: functional and evolutionary insights from comparative gene family classification and analysis
Frech, C., & Chen, N. (2013) · BMC Genomics · doi:10.1186/1471-2164-14-427 · Cited by 82
Mathematical Models of Within-Host and Transmission Dynamics to Determine Effects of Malaria Interventions in a Variety of Transmission Settings
Eckhoff, P. A. (2013) · American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.12-0007 · Cited by 79
Differential Patterns of IgG Subclass Responses to Plasmodium falciparum Antigens in Relation to Malaria Protection and RTS,S Vaccination
Dobaño, C., Santano, R., Vidal, M., Jiménez, A., Jairoce, C., Ubillos, I., Dosoo, D., Aguilar, R., Williams, N. A., Díez‐Padrisa, N., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00439 · Cited by 84
Safety and Immunogenicity of Heterologous Prime-Boost Immunisation with Plasmodium falciparum Malaria Candidate Vaccines, ChAd63 ME-TRAP and MVA ME-TRAP, in Healthy Gambian and Kenyan Adults
Ogwang, C., Afolabi, M. O., Kimani, D., Jagne, Y. J., Hodgson, S. H. C., Bliss, C. M., Duncan, C. J. A., Collins, K. A., Garcia-Knight, M., Kimani, E., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0057726 · Cited by 85
Blood Stage Malaria Disrupts Humoral Immunity to the Pre-erythrocytic Stage Circumsporozoite Protein
Keitany, G. J., Kim, K. S., Krishnamurty, A. T., Hondowicz, B. D., Hahn, W. O., Dambrauskas, N., Sather, D. N., Vaughan, A. M., Kappe, S. H. I., & Pepper, M. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.11.060 · Cited by 76
Targeting regulatory T cells to improve vaccine immunogenicity in early life
Ndure, J., & Flanagan, K. L. (2014) · Frontiers in Microbiology · doi:10.3389/fmicb.2014.00477 · Cited by 78
Full-Length Plasmodium falciparum Circumsporozoite Protein Administered with Long-Chain Poly(I·C) or the Toll-Like Receptor 4 Agonist Glucopyranosyl Lipid Adjuvant-Stable Emulsion Elicits Potent Antibody and CD4+T Cell Immunity and Protection in Mice
Kastenmüller, K., Espinosa, D. A., Trager, L., Stoyanov, C. T., Salazar, A. Μ., Pokalwar, S., Singh, S. P., Dutta, S., Ockenhouse, C. F., Zavala, F. P., et al. (2012) · Infection and Immunity · doi:10.1128/iai.01108-12 · Cited by 78
Virus Like Particles as Immunogens and Universal Nanocarriers
Naskalska, A., & Pyrć, K. (2015) · Polish Journal of Microbiology · doi:10.33073/pjm-2015-001 · Cited by 77
Immunological markers of Plasmodium vivax exposure and immunity: a systematic review and meta-analysis
Cutts, J. C., Powell, R., Agius, P. A., Beeson, J. G., Simpson, J. A., & Fowkes, F. J. I. (2014) · BMC Medicine · doi:10.1186/s12916-014-0150-1 · Cited by 78
STING-Licensed Macrophages Prime Type I IFN Production by Plasmacytoid Dendritic Cells in the Bone Marrow during Severe Plasmodium yoelii Malaria
Spaulding, E., Fooksman, D., Moore, J. M. R., Saidi, A., Feintuch, C. M., Reizis, B., Chorro, L., Daily, J. P., & Lauvau, G. S. (2016) · PLoS Pathogens · doi:10.1371/journal.ppat.1005975 · Cited by 76
Inflammatory parameters associated with systemic reactogenicity following vaccination with adjuvanted hepatitis B vaccines in humans
Burny, W., Marchant, A., Hervé, C., Callegaro, A., Caubet, M., Fissette, L. A., Gheyle, L., Legrand, C., N'Dour, C. T., Silva, F. T. D., et al. (2019) · Vaccine · doi:10.1016/j.vaccine.2019.02.015 · Cited by 74
Repeated clinical malaria episodes are associated with modification of the immune system in children
Bediako, Y., Adams, R., Reid, A. J., Valletta, J. J., Ndungu, F. M., Sodenkamp, J., Mwacharo, J. K., Ngoi, J. M., Kimani, D., Kai, O. K., et al. (2019) · BMC Medicine · doi:10.1186/s12916-019-1292-y · Cited by 73
Towards Eradication of Malaria: Is the WHO’s RTS,S/AS01 Vaccination Effective Enough?
Arora, N., Anbalagan, L. C., & Pannu, A. K. (2021) · Risk Management and Healthcare Policy · doi:10.2147/rmhp.s219294 · Cited by 80
Challenges and responses in human vaccine development
Kaufmann, S. H. E., McElrath, M. J., Lewis, D. J., & Giudice, G. D. (2014) · Current Opinion in Immunology · doi:10.1016/j.coi.2014.01.009 · Cited by 74
Identification of highly-protective combinations of Plasmodium vivax recombinant proteins for vaccine development
França, C. T., White, M. T., He, W., Hostetler, J. B., Brewster, J., Frato, G., Malhotra, I. J., Gruszczyk, J., Huon, C., Lin, E., et al. (2017) · eLife · doi:10.7554/elife.28673 · Cited by 74
Clinical applications of attenuated MVA poxvirus strain
Gómez, C. E., Perdiguero, B., García‐Arriaza, J., & Estéban, M. (2013) · Expert Review of Vaccines · doi:10.1586/14760584.2013.845531 · Cited by 73
Pyrethroid insecticides maintain repellent effect on knock-down resistant populations of Aedes aegypti mosquitoes
Bowman, N. M., Akialis, K., Cave, G., Barrera, R., Apperson, C. S., & Meshnick, S. R. (2018) · PLoS ONE · doi:10.1371/journal.pone.0196410 · Cited by 72
Plasmodium falciparum Resistance to Artemisinin Derivatives and Piperaquine: A Major Challenge for Malaria Elimination in Cambodia
Duru, V., Witkowski, B., & Ménard, D. (2016) · American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.16-0234 · Cited by 77
Identification of Targets of CD8+ T Cell Responses to Malaria Liver Stages by Genome-wide Epitope Profiling
Hafalla, J. C. R., Bauza, K., Friesen, J., González‐Aseguinolaza, G., Hill, A. V. S., & Matuschewski, K. (2013) · PLoS Pathogens · doi:10.1371/journal.ppat.1003303 · Cited by 73
Malaria Vaccines: Progress to Date
Stanisic, D. I., & Good, M. F. (2023) · BioDrugs · doi:10.1007/s40259-023-00623-4 · Cited by 83
Research priorities for the development and implementation of serological tools for malaria surveillance
Elliott, S. R., Fowkes, F. J. I., Richards, J. S., Reiling, L., Drew, D. R., & Beeson, J. G. (2014) · F1000Prime Reports · doi:10.12703/p6-100 · Cited by 70
Malaria vaccine R&D in the Decade of Vaccines: Breakthroughs, challenges and opportunities
Birkett, A. J., Moorthy, V., Loucq, C., Chitnis, C. E., & Kaslow, D. C. (2013) · Vaccine · doi:10.1016/j.vaccine.2013.02.040 · Cited by 74
Robust antibody and CD8+ T-cell responses induced by P. falciparum CSP adsorbed to cationic liposomal adjuvant CAF09 confer sterilizing immunity against experimental rodent malaria infection
Espinosa, D. A., Christensen, D., Muñoz, C. A., Singh, S. P., Locke, E., Andersen, P. L., & Zavala, F. P. (2017) · npj Vaccines · doi:10.1038/s41541-017-0011-y · Cited by 68
Phase 1b Randomized Trial and Follow-Up Study in Uganda of the Blood-Stage Malaria Vaccine Candidate BK-SE36
Palacpac, N., Ntege, E. H., Yeka, A., Balikagala, B., Suzuki, N., Shirai, H., Yagi, M., Ito, K., Fukushima, W., Hirota, Y., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0064073 · Cited by 72
Longitudinal estimation of Plasmodium falciparum prevalence in relation to malaria prevention measures in six sub-Saharan African countries
DRAKELEY, C. J., Abdulla, S., Agnandji, S. T., Fernandes, J. F., Kremsner, P. G., Lell, B., Mewono, L., Bache, E. B., Mihayo, M., Juma, O. A., et al. (2017) · Malaria Journal · doi:10.1186/s12936-017-2078-3 · Cited by 69
Safety profile of the RTS,S/AS01 malaria vaccine in infants and children: additional data from a phase III randomized controlled trial in sub-Saharan Africa
Mendoza, Y. G., Garric, E., Leach, A. J., Lievens, M., Ofori‐Anyinam, O., Pirçon, J., Stegmann, J., Vandoolaeghe, P., Otieno, L., Otieno, W., et al. (2019) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2019.1586040 · Cited by 103
Multifunctional Antibodies Are Induced by the RTS,S Malaria Vaccine and Associated With Protection in a Phase 1/2a Trial
Kurtovic, L., Atre, T., Feng, G., Wines, B. D., Chan, J.-A., Boyle, M. J., Drew, D. R., Hogarth, P. M., Fowkes, F. J. I., Bergmann‐Leitner, E. S., et al. (2020) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiaa144 · Cited by 73
Placebo use in vaccine trials: Recommendations of a WHO expert panel
Rid, A., Saxena, A., Baqui, A. H., Bhan, A., Bines, J. E., Bouësseau, M.-C., Caplan, A. L., Colgrove, J. K., Dhai, A., Gómez-Díaz, R. A., et al. (2014) · Vaccine · doi:10.1016/j.vaccine.2014.04.022 · Cited by 69
Nanomimics of Host Cell Membranes Block Invasion and Expose Invasive Malaria Parasites
Najer, A., Wu, D., Bieri, A., Brand, F., Palivan, C. G., Beck, H., & Meier, W. P. (2014) · ACS Nano · doi:10.1021/nn5054206 · Cited by 71
Application of radiation technology in vaccines development
Seo, H. S. (2015) · Clinical and Experimental Vaccine Research · doi:10.7774/cevr.2015.4.2.145 · Cited by 70
Combination of adjuvants: the future of vaccine design
Mount, A. M., Koernig, S., Silva, A., Drane, D. P., Maraskovsky, E., & Morelli, A. B. (2013) · Expert Review of Vaccines · doi:10.1586/14760584.2013.811185 · Cited by 70
Long-term incidence of severe malaria following RTS,S/AS01 vaccination in children and infants in Africa: an open-label 3-year extension study of a phase 3 randomised controlled trial
Tinto, H., Otieno, W., Gesase, S., Sorgho, H., Otieno, L., Liheluka, E., Valéa, I., Sing’oei, V., Malabeja, A., Valia, D., et al. (2019) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(19)30300-7 · Cited by 66
The Ultra-Potent and Selective TLR8 Agonist VTX-294 Activates Human Newborn and Adult Leukocytes
Dowling, D. J., Tan, Z. W., Prokopowicz, Z. M., Palmer, C. D., Matthews, M.-A. H., Dietsch, G. N., Hershberg, R. M., & Levy, O. (2013) · PLoS ONE · doi:10.1371/journal.pone.0058164 · Cited by 66
Evaluation of the immune response to RTS,S/AS01 and RTS,S/AS02 adjuvanted vaccines
Leroux-Roels, G. G., Leroux‐Roels, I., Clément, F., Ofori‐Anyinam, O., Lievens, M., Jongert, E., Moris, P., Ballou, W. R., & Cohen, J. (2014) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.29375 · Cited by 66
Adjuvant Systems for vaccines: 13 years of post-licensure experience in diverse populations have progressed the way adjuvanted vaccine safety is investigated and understood
Laupèze, B., Hervé, C., Pasquale, A. D., & Silva, F. T. D. (2019) · Vaccine · doi:10.1016/j.vaccine.2019.07.098 · Cited by 71
Sulfonamide inhibition studies of the η-class carbonic anhydrase from the malaria pathogen Plasmodium falciparum
Vullo, D., Prete, S. D., Fisher, G. M., Andrews, K. T., Poulsen, S., Capasso, C., & Supuran, C. T. (2014) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2014.12.009 · Cited by 66
Reversible Conformational Change in the Plasmodium falciparum Circumsporozoite Protein Masks Its Adhesion Domains
Herrera, R., Anderson, C., Kumar, K., Molina-Cruz, A., Nguyen, V., Burkhardt, M., Reiter, K., Shimp, R. L., Howard, R. F., Srinivasan, P., et al. (2015) · Infection and Immunity · doi:10.1128/iai.02676-14 · Cited by 68
Artemisinin resistance and malaria elimination: Where are we now?
Hanboonkunupakarn, B., Tärning, J., Pukrittayakamee, S., & Chotivanich, K. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.876282 · Cited by 65
Bacterial superglue generates a full-length circumsporozoite protein virus-like particle vaccine capable of inducing high and durable antibody responses
Janitzek, C. M., Matondo, S., Thrane, S., Nielsen, M. A., Kavishe, R. A., Mwakalinga, S., Theander, T. G., Salanti, A., & Sander, A. F. (2016) · Malaria Journal · doi:10.1186/s12936-016-1574-1 · Cited by 64
A systematic review and meta-analysis on the safety of newly adjuvanted vaccines among children
Stassijns, J., Bollaerts, K., Baay, M. F. D., & Verstraeten, T. (2015) · Vaccine · doi:10.1016/j.vaccine.2015.12.024 · Cited by 63
Liposomes containing monophosphoryl lipid A and QS-21 serve as an effective adjuvant for soluble circumsporozoite protein malaria vaccine FMP013
Genito, C. J., Beck, Z., Phares, T. W., Kalle, F., Limbach, K. J., Stefaniak, M. E., Patterson, N. B., Bergmann‐Leitner, E. S., Waters, N. C., Matyas, G. R., et al. (2017) · Vaccine · doi:10.1016/j.vaccine.2017.05.070 · Cited by 59
Antimalarial Activity of the Myxobacterial Macrolide Chlorotonil A
Held, J., Woldearegai, T. G., Kalesse, M., Jansen, R., Gerth, K., Müller, R., & Mordmüller, B. G. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.03326-14 · Cited by 64
Antibody and B cell responses to Plasmodium sporozoites
Dups, J., Pepper, M., & Cockburn, I. A. (2014) · Frontiers in Microbiology · doi:10.3389/fmicb.2014.00625 · Cited by 65
New Vaccines for the World's Poorest People
Hotez, P. J., Bottazzi, M. E., & Strych, U. (2015) · Annual Review of Medicine · doi:10.1146/annurev-med-051214-024241 · Cited by 60
CD8 T-cell-mediated protection against liver-stage malaria: lessons from a mouse model
Budimir, N., & Harty, J. T. (2014) · Frontiers in Microbiology · doi:10.3389/fmicb.2014.00272 · Cited by 60
Updates on Malaria Epidemiology and Prevention Strategies
Sanz, M., Berzosa, P. J., & Norman, F. (2023) · Current Infectious Disease Reports · doi:10.1007/s11908-023-00805-9 · Cited by 71
Detection of low-density Plasmodium falciparum infections using amplicon deep sequencing
Early, A. M., Daniels, R. F., Farrell, T. M., Grimsby, J., Volkman, S. K., Wirth, D. F., MacInnis, B. L., & Neafsey, D. E. (2019) · Malaria Journal · doi:10.1186/s12936-019-2856-1 · Cited by 59
Combining Viral Vectored and Protein-in-adjuvant Vaccines Against the Blood-stage Malaria Antigen AMA1: Report on a Phase 1a Clinical Trial
Hodgson, S. H. C., Choudhary, P., Elias, S. C., Milne, K. H., Rampling, T., Biswas, S., Poulton, I. D., Miura, K., Douglas, A. D., Alanine, D. G. W., et al. (2014) · Molecular Therapy · doi:10.1038/mt.2014.157 · Cited by 58
Status of vaccine research and development of vaccines for malaria
Birkett, A. J. (2016) · Vaccine · doi:10.1016/j.vaccine.2015.12.074 · Cited by 58
The Repeat Region of the Circumsporozoite Protein is Critical for Sporozoite Formation and Maturation in Plasmodium
Ferguson, D. J. P., Balaban, A. E., Patzewitz, E., Wall, R. J., Hopp, C. S., Poulin, B., Mohmmed, A., Malhotra, P., Coppi, A., Sinnis, P., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0113923 · Cited by 57
Plasmodium falciparum pre-erythrocytic stage vaccine development
Molina-Franky, J., Cuy-Chaparro, L., Camargo, A., Reyes, C., Gómez, M., Jiménez, D. R. S., Patarroyo, M. A., & Patarroyo, M. E. (2020) · Malaria Journal · doi:10.1186/s12936-020-3141-z · Cited by 62
Global diversity and balancing selection of 23 leading Plasmodium falciparum candidate vaccine antigens
Naung, M. T., Martin, E., Munro, J. E., Mehra, S., Guy, A. J., Laman, M., Harrison, G. L. A., Tavul, L., Hetzel, M. W., Kwiatkowski, D. P., et al. (2022) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1009801 · Cited by 55
Community perceptions of a malaria vaccine in the Kintampo districts of Ghana
Febir, L. G., Asante, K. P., Dzorgbo, D. S., Senah, K., Letsa, T. S., & Owusu‐Agyei, S. (2013) · Malaria Journal · doi:10.1186/1475-2875-12-156 · Cited by 56
Translating the Immunogenicity of Prime-boost Immunization With ChAd63 and MVA ME-TRAP From Malaria Naive to Malaria-endemic Populations
Kimani, D., Jagne, Y. J., Cox, M., Kimani, E. N., Bliss, C. M., Gitau, E., Ogwang, C., Afolabi, M. O., Bowyer, G., Collins, K. A., et al. (2014) · Molecular Therapy · doi:10.1038/mt.2014.109 · Cited by 54
Sporozoite Immunization of Human Volunteers under Mefloquine Prophylaxis Is Safe, Immunogenic and Protective: A Double-Blind Randomized Controlled Clinical Trial
Bijker, E. M., Schats, R., Obiero, J. M., Behet, M. C., van Gemert, G., van de Vegte‐Bolmer, M., Graumans, W., van Lieshout, L., Bastiaens, G. J. H., Teelen, K., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0112910 · Cited by 54
Molecular Farming in Artemisia annua, a Promising Approach to Improve Anti-malarial Drug Production
Pulice, G., Pelaz, S., & Matías-Hernández, L. (2016) · Frontiers in Plant Science · doi:10.3389/fpls.2016.00329 · Cited by 53
A Second Chance to Tackle African Malaria Vector Mosquitoes that Avoid Houses and Don't Take Drugs
Killeen, G. F. (2013) · American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.13-0065 · Cited by 55
N-Myristoylation as a Drug Target in Malaria: Exploring the Role of N-Myristoyltransferase Substrates in the Inhibitor Mode of Action
Schlott, A., Holder, A. A., & Tate, E. W. (2018) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.7b00203 · Cited by 53
Immunogenicity and Safety of the M72/AS01E Candidate Vaccine Against Tuberculosis: A Meta-Analysis
Ji, Z., Jian, M., Chen, T., Luo, L., Li, L., Dai, X., Bai, R., Ding, Z., Bi, Y., Wen, S., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02089 · Cited by 55
Efficacy of phase 3 trial of RTS, S/AS01 malaria vaccine: The need for an alternative development plan
Mahmoudi, S., & Keshavarz, H. (2017) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2017.1295906 · Cited by 58
Vaccination with a structure-based stabilized version of malarial antigen Pfs48/45 elicits ultra-potent transmission-blocking antibody responses
McLeod, B., Mabrouk, M. T., Miura, K., Ravichandran, R., Kephart, S. M., Hailemariam, S., Pham, T., Semesi, A., Kucharska, I., Kundu, P., et al. (2022) · Immunity · doi:10.1016/j.immuni.2022.07.015 · Cited by 52
Safety, Immunogenicity and Efficacy of Prime-Boost Vaccination with ChAd63 and MVA Encoding ME-TRAP against Plasmodium falciparum Infection in Adults in Senegal
Mensah, V. A., Gueye, A., Ndiaye, M., Edwards, N. J., Wright, D., Anagnostou, N. A., Syll, M., Ndaw, A., Abiola, A., Bliss, C. M., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0167951 · Cited by 60
What Is Known about the Immune Response Induced by Plasmodium vivax Malaria Vaccine Candidates?
López, C., Yepes-Pérez, Y., Hincapié-Escobar, N., Díaz-Arévalo, D., & Patarroyo, M. A. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00126 · Cited by 54
Interactions of Anopheles gambiae Odorant-binding Proteins with a Human-derived Repellent
Murphy, E. J., Booth, J. C., Davrazou, F., Port, A. M., & Jones, D. N. M. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.436386 · Cited by 51
Management of severe paediatric malaria in resource-limited settings
Maitland, K. (2015) · BMC Medicine · doi:10.1186/s12916-014-0263-6 · Cited by 51
Successful vaccines for naturally occurring protozoal diseases of animals should guide human vaccine research. A review of protozoal vaccines and their designs
McAllister, M. Μ. (2014) · Parasitology · doi:10.1017/s0031182013002060 · Cited by 51
Biomarkers of Safety and Immune Protection for Genetically Modified Live Attenuated Leishmania Vaccines Against Visceral Leishmaniasis – Discovery and Implications
Gannavaram, S., Dey, R., Avishek, K., Selvapandiyan, A., Salotra, P., & Nakhasi, H. L. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00241 · Cited by 51
Biologics to treat substance use disorders: Current status and new directions
Pravetoni, M. (2016) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2016.1212785 · Cited by 52
Vaccination With Sporozoites: Models and Correlates of Protection
Goh, Y. S., McGuire, D., & Rénia, L. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01227 · Cited by 51
A delayed fractionated dose RTS,S AS01 vaccine regimen mediates protection via improved T follicular helper and B cell responses
Pallikkuth, S., Chaudhury, S., Lu, P., Pan, L., Jongert, E., Wille-Reece, U., & Pahwa, S. G. (2020) · eLife · doi:10.7554/elife.51889 · Cited by 50
The RTS,S/AS01 malaria vaccine in children 5 to 17 months of age at first vaccination
Vandoolaeghe, P., & Schuerman, L. (2016) · Expert Review of Vaccines · doi:10.1080/14760584.2016.1236689 · Cited by 52
Randomized, controlled trial of the long term safety, immunogenicity and efficacy of RTS,S/AS02D malaria vaccine in infants living in a malaria-endemic region
Abdulla, S., Salim, N., Machera, F., Kamata, R., Juma, O. A., Shomari, M., Kubhoja, S. D., Mohammed, A., Mwangoka, G., Aebi, T., et al. (2013) · Malaria Journal · doi:10.1186/1475-2875-12-11 · Cited by 51
Clinical Development of RTS,S/AS Malaria Vaccine: A Systematic Review of Clinical Phase I–III Trials
Agnandji, S. T., Fernandes, J. F., Bache, E. B., & Ramharter, M. (2015) · Future Microbiology · doi:10.2217/fmb.15.90 · Cited by 54
Neutralising antibodies block the function of Rh5/Ripr/CyRPA complex during invasion of Plasmodium falciparum into human erythrocytes
Healer, J., Wong, W., Thompson, J. K., He, W., Birkinshaw, R. W., Miura, K., Long, C. A., Soroka, V., Søgaard, M., Jørgensen, T. R., et al. (2019) · Cellular Microbiology · doi:10.1111/cmi.13030 · Cited by 49
Avid binding by B cells to the Plasmodium circumsporozoite protein repeat suppresses responses to protective subdominant epitopes
Chatterjee, D., Lewis, F. J., Sutton, H. J., Kaczmarski, J. A., Gao, X., Cai, Y., McNamara, H. A., Jackson, C. J., & Cockburn, I. A. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.108996 · Cited by 51
A Full-Length Plasmodium falciparum Recombinant Circumsporozoite Protein Expressed by Pseudomonas fluorescens Platform as a Malaria Vaccine Candidate
Noe, A. R., Espinosa, D. A., Li, X., Coelho-dos-Reis, J. G. A., Funakoshi, R., Giardina, S. L., Jin, H., Retallack, D. M., Haverstock, R., Allen, J. R., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0107764 · Cited by 48
Synthesis and antimalarial activity of prodigiosenes
Marchal, E., Smithen, D. A., Uddin, M. I., Robertson, A. W., Jakeman, D. L., Mollard, V., Goodman, C. D., MacDougall, K. S., McFarland, S. A., McFadden, G. I., et al. (2014) · Organic & Biomolecular Chemistry · doi:10.1039/c3ob42548g · Cited by 48
RTS,S/AS01 malaria vaccine (Mosquirix®): a profile of its use
Syed, Y. Y. (2022) · Drugs & Therapy Perspectives · doi:10.1007/s40267-022-00937-3 · Cited by 56
Current approaches to malaria vaccines
Duffy, P. E. (2022) · Current Opinion in Microbiology · doi:10.1016/j.mib.2022.102227 · Cited by 46
Vaccination in a humanized mouse model elicits highly protective PfCSP-targeting anti-malarial antibodies
Kratochvil, S., Shen, C., Lin, Y., Xu, K. Y., Nair, U., Pereira, L. D. S., Tripathi, P., Arnold, J., Chuang, G., Melzi, E., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.10.017 · Cited by 46
A genetically-engineered Plasmodium falciparum parasite vaccine provides protection from controlled human malaria infection
Murphy, S., Vaughan, A., Kublin, J., Fishbauger, M., Seilie, A., Cruz, K., Mankowski, T., Firat, M., Magee, S., Betz, W., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abn9709 · Cited by 42
Viral Vector Malaria Vaccines Induce High-Level T Cell and Antibody Responses in West African Children and Infants
Bliss, C. M., Drammeh, A., Bowyer, G., Sanou, G. S., Jagne, Y. J., Ouédraogo, O., Edwards, N. J., Tarama, C., Ouédraogo, N., Ouédraogo, M., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2016.11.003 · Cited by 49
Potent antibody lineage against malaria transmission elicited by human vaccination with Pfs25
McLeod, B., Miura, K., Scally, S. W., Bosch, A., Nguyen, N. T. K., Shin, H., Kim, D., Volkmuth, W., Rämisch, S., Chichester, J. A., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11980-6 · Cited by 45
Antibody-guided structure-based vaccines
Kwong, P. D., DeKosky, B. J., & Ulmer, J. B. (2020) · Seminars in Immunology · doi:10.1016/j.smim.2020.101428 · Cited by 43
Text Recycling in Scientific Writing
Moskovitz, C. A. (2018) · Science and Engineering Ethics · doi:10.1007/s11948-017-0008-y · Cited by 46
Dectin-1 activation unlocks IL12A expression and reveals the TH1 potency of neonatal dendritic cells
Lemoine, S., Jaron, B., Tabka, S., Ettreiki, C., Dériaud, E., Zhivaki, D., Ray, C. L., Launay, O., Majlessi, L., Tissières, P., et al. (2015) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2015.02.030 · Cited by 44
Baculovirus-Vectored Multistage Plasmodium vivax Vaccine Induces Both Protective and Transmission-Blocking Immunities against Transgenic Rodent Malaria Parasites
Mizutani, M., Iyori, M., Blagborough, A. M., Fukumoto, S., Funatsu, T., Sinden, R. E., & Yoshida, S. (2014) · Infection and Immunity · doi:10.1128/iai.02040-14 · Cited by 44
Safety, toxicity and immunogenicity of a malaria vaccine based on the circumsporozoite protein (FMP013) with the adjuvant army liposome formulation containing QS21 (ALFQ)
Cawlfield, A., Genito, C. J., Beck, Z., Bergmann‐Leitner, E. S., Bitzer, A. A., Soto, K., Zou, X., Hadiwidjojo, S., Gerbasi, V. R., Mullins, A. B., et al. (2019) · Vaccine · doi:10.1016/j.vaccine.2019.05.059 · Cited by 43

Authors: The RTS, S. C. T. P.
Affiliations: Program for Appropriate Technology in Health (US)
Corresponding author: The RTS,S Clinical Trials Partnership
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2012-12-13
Volume: 367
Issue: 24
Pages: 2284-2295
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa1208394
PMC: PMC10915853
OpenAlex: W2244674613
Cited by: 752
References: 31
Citations by year: 2026: 18 · 2025: 29 · 2024: 35 · 2023: 38 · 2022: 36 · 2021: 42 · 2020: 45 · 2019: 47 · 2018: 40 · 2017: 58 · 2016: 67 · 2015: 74 · 2014: 111 · 2013: 103 · 2012: 7
FWCI: 91.09
Type: journal article
Language: en
Open access: hybrid
doi.org
Licence: other-oa
Locations: New England Journal of Medicine (publishedVersion, other-oa)
PubMed (publishedVersion)
Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
IHI Repository (acceptedVersion)
PubMed Central (acceptedVersion)
LSHTM Research Online (London School of Hygiene and Tropical Medicine) (acceptedVersion)
Funders: Bill and Melinda Gates Foundation
GlaxoSmithKline
Wellcome Trust (092654)
National Institutes of Health (CC999999)
Topics: Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Malaria Research and Control
Life Sciences › Immunology and Microbiology › Microbiology › Bacterial Infections and Vaccines
Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Travel-related health issues
Keywords: RTS,S/AS01, malaria vaccine, infants, vaccine efficacy, clinical malaria, severe malaria, circumsporozoite protein, co-administration, immunogenicity, vaccine safety, Plasmodium falciparum, African infants, malaria prevention, vaccine adverse events
MeSH terms: Africa, Female, Humans, Immunization Schedule, Infant, Male, Plasmodium falciparum, Vaccines, Synthetic, Incidence, Proportional Hazards Models, Malaria, Falciparum, Treatment Outcome, Malaria Vaccines, Intention to Treat Analysis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

A Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African Infants

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks